BLCO (Bausch + Lomb Corporation) Stock | Pipeline, Insider Trades & Financials

Jul 29, 2026

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Bausch + Lomb Corporation reported strong financial results for the second quarter of 2026, highlighting broad-based revenue growth and margin expansion. The company emphasized its ongoing progress in executing its three-year growth plan, which was initially presented at the Investor Day last November. The positive performance indicates effective management and operational improvements.

Jul 16, 2026

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

Bausch + Lomb Corporation has announced the launch of its EyeGility™ Inserter preloaded IOL delivery system in the United States. This new system is designed to enhance the surgical experience for eye surgeons and is part of the enVista IOL platform, known for its glistening-free optic. The product aims to meet the diverse needs of patients.

Jul 9, 2026

BLCOPhases

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

Bausch + Lomb Corporation announced topline results from its Phase 2 study of BL1107 for glaucoma. The study failed to meet its primary endpoint, as it could not replicate the visual function improvements seen in a previous Phase 1/2a study after 28 days of treatment. This outcome raises concerns about the efficacy of the candidate.

Jul 9, 2026

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

Bausch + Lomb has launched Orphia™, an AI-driven digital health platform aimed at streamlining tools for eye care providers. This initiative allows physicians to focus more on patient care rather than managing various disconnected technologies. The platform is designed to be inclusive for all eye care professionals, enhancing overall service delivery.

Jul 6, 2026

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

Bausch + Lomb is set to announce its financial results for the second quarter of 2026 on July 29. The announcement will provide insights into the company's performance during this period. Investors and stakeholders are likely to pay close attention to the results for future projections.

Jul 1, 2026

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

Bausch + Lomb has released new data indicating that effectively addressing dry eye symptoms can significantly enhance patients' quality of life. The findings suggest a correlation between symptom management and reduced anxiety, as well as increased self-confidence. This highlights the importance of treating dry eye conditions.

Apr 29, 2026

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook Revenue of $1.244 Billion Revenue Grew 9% as Reported and 6% on a Constant Currency 1 Basis Compared to

Bausch + Lomb Corporation reported strong first-quarter 2026 results with revenue reaching $1.244 billion, reflecting a 9% growth compared to the previous year. The company attributed its performance to robust sales in key areas, particularly in Pharmaceuticals. As a result, they have raised their full-year revenue and adjusted EBITDA guidance due to anticipated stronger business performance. However, they recorded a GAAP net loss of $71 million, although this was an improvement from the previous year's loss. The ongoing use of non-GAAP measures for analysis highlights their focus on operational efficiencies and revenue generation.

Feb 18, 2026

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Re

Bausch + Lomb Corporation reported its fourth-quarter and full-year financial results for 2025, showcasing significant revenue growth across several segments. The company achieved an impressive EBITDA margin expansion and increased revenues in dry eye products and Vision Care. However, despite these successes, Bausch + Lomb faced a GAAP net loss of $58 million in the fourth quarter and a total net loss of $360 million for the year. The company remains focused on its financial targets and operational improvements.

Jan 2, 2026

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Bausch + Lomb Corporation has successfully refined its credit agreement, resulting in a new tranche of $2.8 billion term B loans. This refinancing enables Bausch + Lomb to clear its outstanding term B loans due in 2028 and 2031, while securing lower interest margins. The amortization rate for the new loans is 1.00%, and the first installment is due by June 30, 2026. This move reflects the company's ongoing commitment to enhancing cash flow and maintaining a strong position in the eye health market.

Dec 17, 2025

Bausch + Lomb Announces Two Board of Directors Appointments

Bausch + Lomb Corporation has announced the appointments of Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. Dr. Alfonso, an internationally recognized ophthalmologist, and Collis, former CEO of Cencora, Inc., bring extensive experience to the board. Their appointments come after recent changes in the board's composition, and leadership emphasizes their potential role in driving the company's strategic growth. Bausch + Lomb continues to focus on innovation in eye health.

Dec 12, 2025

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Bausch + Lomb Corporation has announced a significant refinancing initiative, allocating $2.8 billion towards new term B loans to replace existing loans due in 2028 and 2031. This refinancing aims to reduce applicable margins and extend the maturity of certain loans, enhancing the company's financial position. The transactions are expected to close in the first quarter of 2026, though uncertainties remain about their completion on the proposed terms.

Nov 13, 2025

BLCOConferences/Events

▼ -5.5%on this news

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Bausch + Lomb Corporation outlined its transformation and growth strategy at an investor day event held in New York City. The company is transitioning to focus on accountability and innovation and is targeting a 5-7% annual revenue growth through 2028. Key financial goals include continuous improvements in margin and a double-digit growth rate for earnings per share. Leadership also emphasized an evolving product pipeline that promises to push the boundaries of ocular science.

Oct 29, 2025

Bausch + Lomb Announces Third-Quarter 2025 Results Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP) 1 of $243 Million Adjusted EBITDA Excluding A

Bausch + Lomb reported its third-quarter 2025 financial results with a revenue of $1.281 billion, marking a 7% increase from the previous year. Despite this growth, the company experienced a net loss of $28 million, contrasting with a profit in the prior year. The Pharmaceuticals and Vision Care segments led the revenue growth, while adjusted EBITDA reached $243 million, up from $212 million a year ago. The company has updated its financial outlook for the full year, maintaining revenue growth expectations but slightly adjusting EBITDA targets.

Bausch + Lomb Announces Second-Quarter 2025 Results Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP) 1 of $191 Million Adjusted EBITDA Excluding

Bausch + Lomb Corporation announced its second-quarter 2025 financial results, reporting a revenue increase to $1.278 billion, a 5% rise from the previous year. The company raised its full-year guidance, citing strong business performance and currency tailwinds. However, despite these gains, Bausch + Lomb reported a net loss of $62 million and an operating loss of $11 million, highlighting challenges in its operations. The adjusted EBITDA decreased year-over-year, pointing to ongoing pricing pressures within its product segments.

Jun 26, 2025

Bausch + Lomb Announces Closing of Upsized 675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Bausch + Lomb Corporation has announced the successful closing of an upsized offering of $675 million in senior secured notes, which are set to mature in 2031. As part of this financial maneuvering, the company has also refinanced a portion of its existing credit facilities, including a new $2.325 billion term loan facility, enhancing its liquidity and flexibility. The new financial structures include adjustments to interest rates and amortization schedules, aiming to streamline its debt obligations and improve capital management. This strategic refinancing positions Bausch + Lomb favorably for future operations and investments.

Jun 18, 2025

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Bausch + Lomb Corporation announced the successful pricing of its upsized senior secured notes offering, increasing from $600 million to $675 million. The company intends to use the proceeds to refinance existing credit agreements and enhance its financial position. Alongside this offering, Bausch + Lomb is looking to secure additional financing through a New Term B Loan Facility valued at $2.325 billion. The closing of these transactions is anticipated on June 26, 2025, although success is not guaranteed.

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

Bausch + Lomb announced the launch of a $600 million senior secured notes offering and a partial refinancing of its credit agreement. This includes obtaining a new $2.2 billion term B loan facility and an $800 million revolving credit facility. The proceeds are intended to repay existing debts and support general corporate objectives. However, the completion of these transactions is subject to market conditions, and the notes will not be registered under the Securities Act.

Bausch + Lomb Announces First-Quarter 2025 Results Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR D (non-GAAP) 1 of $126 Million R

Bausch + Lomb Corporation reported its first-quarter 2025 financial results, with revenue of $1.137 billion, marking a 3% increase from the previous year. However, the company faced a GAAP net loss of $212 million, up from $167 million a year ago, and reported an operating loss of $83 million attributable to increased selling and promotion costs. The company has updated its full-year guidance to account for a one-time impact from the enVista intraocular lenses voluntary recall and foreign exchange fluctuations. Positive developments included revenue growth in its contact lens and surgical segments, alongside the return of enVista lenses to the market.

Feb 19, 2025

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Mill

Bausch + Lomb Corporation reported its financial results for the fourth quarter and full year of 2024, revealing significant revenue growth across all segments. The company's revenue for Q4 was $1.280 billion, a 9% increase compared to the previous year, while full-year revenue reached $4.791 billion, marking a 16% rise. Despite these gains, the company also recorded a net loss of $3 million in Q4 and $317 million for the full year. Looking forward, Bausch + Lomb anticipates further growth driven by its strong pipeline and market demand.

Oct 30, 2024

Bausch + Lomb Announces Third-Quarter 2024 Results Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP) 1 of $212 Million Adjusted EBITDA excluding

Bausch + Lomb Corporation reported its third-quarter 2024 financial results, highlighting a revenue of $1.196 billion, a 19% increase from Q3 2023. The company raised its full-year revenue guidance, attributing growth to successes in various segments, notably Pharmaceuticals. Despite positive trends, net income was only $4 million, recovering from a loss last year, while adjusted earnings per share decreased. The company noted that operational investments may have influenced these financial outcomes.

Jul 31, 2024

Bausch + Lomb Announces Second-Quarter 2024 Results Revenue of $1.216 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million Adjusted EBITDA (non-GAAP) 1 of $209 Million Revenue Grew 17% as Repor

Bausch + Lomb Corporation reported strong financial results for the second quarter of 2024, with revenue of $1.216 billion, representing a 17% increase year-over-year. While the company faced a GAAP net loss of $151 million, it launched innovative products and strengthened its leadership in the dry eye category. The firm raised its guidance for full-year 2024 revenue and adjusted EBITDA, indicating a positive outlook despite the loss. The company also cited robust sales growth across all segments, particularly in the pharmaceuticals area.

Bausch + Lomb Announces First-Quarter 2024 Results Revenue of $1.099 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP) 1 of $180 Million Revenue Grew 18% as Report

Bausch + Lomb Corporation reported its first-quarter 2024 results, achieving revenue of $1.099 billion, up 18% from the previous year. Although the company experienced a net loss of $167 million, it reported significant growth in its Pharmaceuticals segment, with a 66% increase in revenue. The company has raised its full-year revenue growth guidance based on robust performance across all business segments despite headwinds from foreign exchange. Adjusted EBITDA reached $180 million, indicating a positive trend in operational efficiency.

Apr 19, 2024

Bausch + Lomb Receives FDA Approval of LUMIFY® Preservative Free Redness Reliever Eye Drops

Bausch + Lomb has received FDA approval for LUMIFY Preservative Free eye drops, the first over-the-counter preservative-free option for ocular redness. The product reduces redness quickly and has a low incidence of side effects. It is expected to be available in early 2025.

Apr 3, 2024

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Basilea Pharmaceutica announced FDA approval of ZEVTERA® for three indications, including treatment for Staphylococcus aureus bloodstream infections and community-acquired bacterial pneumonia. The approval is seen as a significant milestone, providing 10 years of market exclusivity and addressing critical medical needs.

Feb 28, 2024

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors Richard De Schutter to Retire from Board Following 2024 Annual Meeting

Bausch + Lomb Corporation has appointed Karen L. Ling to its Board of Directors, effective immediately. This decision comes as current director Richard De Schutter prepares for retirement following the 2024 Annual Meeting. Ling, who has significant experience in human capital management and corporate governance, is expected to enhance the board's capabilities during a critical period of global growth for the company. The board will temporarily expand to 11 members during this transition.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance Fourth-Quarter 2023 Financial Results Revenue of $1.173 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54

Bausch + Lomb Corporation reported its fourth-quarter and full-year 2023 financial results, revealing a revenue of $1.173 billion for Q4 and $4.146 billion for the full year. Despite an 18% increase in revenue year-over-year for Q4, the company faced a GAAP net loss of $54 million. The company launched several new products and received FDA approval for a new laser platform, but continued financial challenges and increased expenses impacted overall profitability. The firm is committed to disciplined cost management while aiming for sustained revenue growth in 2024.

Nov 1, 2023

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance Revenues of $1.007 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million Adjusted EBITDA (non-GAAP) 1 of $187

Bausch + Lomb Corporation reported its third-quarter 2023 results, achieving revenues of $1.007 billion, marking a 7% increase year-over-year. The company raised its full-year revenue and adjusted EBITDA guidance, driven by growth in the Vision Care and Surgical segments. Despite these positive earnings, Bausch + Lomb experienced a GAAP net loss of $84 million, up from $18 million a year earlier, partly due to higher operational costs and unfavorable foreign exchange impacts. The company highlighted recent product launches and improvements in sales strategies as pivotal for their ongoing growth.

Sep 29, 2023

Bausch + Lomb Completes Acquisition of XIIDRA Poised for Significant Growth in Prescription Dry Eye Segment

Bausch + Lomb has successfully completed the acquisition of XIIDRA, a prescription eye drop approved for dry eye disease, for up to $2.5 billion. This acquisition positions the company to capitalize on the growing prescription dry eye market, which is expected to experience substantial growth in the coming years. The deal also includes the purchase of libvatrep and AcuStream technology, enhancing their portfolio in ophthalmic solutions. The CEO highlighted the company’s commitment to addressing the needs of millions suffering from dry eye disease.

Sep 14, 2023

Bausch + Lomb Announces Pricing of Senior Secured Notes Offering

Bausch + Lomb Corporation announced the pricing of its $1.4 billion senior secured notes due 2028, which will fund the acquisition of XIIDRA, an eye treatment. The notes will initially be issued by Bausch + Lomb Escrow Corp., with proceeds to be released upon closing of the acquisition. The company plans to borrow an additional $500 million through a term loan facility contingent on acquisition completion. The anticipated closing date for both transactions is around the end of September 2023.

Sep 11, 2023

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of

Bausch + Lomb Corporation has launched a proposed financing plan to support its acquisition of XIIDRA, an ophthalmic solution for dry eye disease. The financing includes a $1.4 billion offering of senior secured notes and plans for a term loan facility totaling $500 million. The issuance of the notes and the loan facility's closing are contingent upon the scheduled completion of the acquisition, projected for the end of September 2023. Several market risks could impact the company's ability to execute these financial strategies as planned.

Sep 6, 2023

Independent Auditors Report To Management of Novartis Pharma AG Report on the Audit of the Abbreviated Financial Statements Opinion We have audited the abbreviated financial statements related to the worldwide rights to

The independent auditor's report for Novartis Pharma AG examined the abbreviated financial statements related to the worldwide rights to Xiidra and other assets. These statements were deemed to fairly represent Novartis' financial position under IFRS standards. Novartis has entered a significant sale agreement with Bausch & Lomb, which includes a closing consideration of $1.75 billion and additional milestone payments. The agreement emphasizes the transition services that will support the continued supply of Xiidra post-sale. However, the report also highlights past financial shortfalls related to direct expenses, indicating ongoing challenges.

Aug 2, 2023

Investor Contacts Media Contacts George Gadkowski T.J. Crawford george.gadkowski bausch.com tj.crawford bausch.com (908) 705-2851 Allison Ryan allison.ryan bausch.com Lainie Keller (877) 354-3705 (toll free) lainie.kelle

Bausch + Lomb Corporation reported its second-quarter 2023 financial results, announcing revenues of $1.035 billion, a 10% increase from the previous year. The company raised its full-year revenue outlook while reaffirming its adjusted EBITDA guidance range. However, it also reported a net loss attributable to Bausch + Lomb of $32 million, primarily impacted by increased selling and administrative expenses due to its status as a standalone entity. Foreign exchange headwinds were noted as negatively affecting overall performance.

Jun 30, 2023

Bausch + Lomb Will Acquire XIIDRA Acquisition Represents Significant Opportunity for Growth in Prescription Dry Eye Segment

Bausch + Lomb Corporation has entered into a definitive agreement to acquire XIIDRA, a prescription eye drop for treating dry eye disease, from Novartis for up to $2.5 billion. This acquisition is viewed as a strategic move to strengthen Bausch + Lomb's position in the ocular surface disease market and is expected to enhance margin growth and earnings. The agreement also includes the acquisition of the investigational compound libvatrep and AcuStream technology. The transaction is anticipated to close by the end of 2023, pending regulatory approvals.

Jun 1, 2023

Investor Contacts: Media Contacts: Allison Ryan Lainie Keller allison.ryan@bausch.com lainie.keller@bausch.com (877) 354-3705 (toll free) (908) 927-1198 (908) 927-0735 Bausch + Lomb Announces Key Leadership Changes

Bausch + Lomb Corporation announced significant changes to its executive leadership team, including the elevation of business unit heads reporting to CEO Brent Saunders. Joseph Gordon will shift to the role of Strategic Advisor, and Louis Yu is slated to retire, prompting a search for a replacement. These adjustments reflect Bausch + Lomb's commitment to leveraging strong leadership to enhance operational efficiency and customer engagement for future growth.

May 18, 2023

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Bausch + Lomb and Novaliq announced FDA approval of MIEBO, the first prescription eye drop targeting tear evaporation for dry eye disease. The approval is based on positive results from pivotal phase 3 trials, addressing a significant need for effective treatment in millions of patients.

May 3, 2023

Investor Contacts Media Contacts Arthur Shannon Lainie Keller arthur.shannon bausch.com lainie.keller bausch.com (908) 927-1198 Allison Ryan allison.ryan bausch.com Kristy Marks (877) 354-3705 (toll free) kristy.marks ba

Bausch + Lomb Corporation reported its first-quarter 2023 financial results, highlighting revenues of $931 million, a 5% increase from the previous year. Despite the revenue growth, the company faced a GAAP net loss of $90 million and an operating loss of $2 million, primarily due to rising expenses associated with its status as a publicly traded company. The CEO emphasized a strong foundation and ongoing strategies to optimize performance and enhance growth in the eye health sector. Additionally, the company made significant product launches and acquisitions during the quarter.

Apr 12, 2023

Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bausch.com lainie.keller@bausch.com (908) 927-1198 Allison Ryan allison.ryan@bausch.com (877) 354-3705 (toll free) (908) 927-0735 Bausch + Lomb

Bausch + Lomb Corporation announced the appointment of Bob Bailey as Executive Vice President and Chief Legal Officer, and Andrew Stewart as President of Ophthalmic Pharmaceuticals, effective April 24, 2023. Bailey has over 25 years of healthcare industry experience and returns to Bausch + Lomb after working at Datavant. Stewart, joining from AbbVie, has a strong background in eye care and pharmaceutical product development. The transitions come as Christina Ackermann steps down, with the company expressing confidence in its new leaders to drive future growth.

Jun 23, 2022

Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller arthur.shannon@bausch.com lainie.keller@bausch.com (908) 927-1198 Allison Ryan allison.ryan@bausch.com Kristy Marks (877) 354-3705 (toll free) kristy.marks@

Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller arthur.shannon@bausch.com lainie.keller@bausch.com (908) 927-1198 Allison Ryan allison.ryan@bausch.com Kristy Marks (877) 354-3705 (toll free) kristy.marks@bausch.com (908) 927-0735 (908) 927-0683 Announces Brett

Jun 8, 2022

Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (908) 927-1198 Allison Ryan allison.ryan@bausch.com Kristy Marks (877) 354-3705 (toll free) k

Investor Contacts: Media Contacts: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (908) 927-1198 Allison Ryan allison.ryan@bausch.com Kristy Marks (877) 354-3705 (toll free) kristy.marks@bausch.com (908) 927-0735 (908) 927-0

May 17, 2022

BAUSCH + LOMB CORPORATION (a business of Bausch Health Companies Inc.) INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets as of

BAUSCH + LOMB CORPORATION (a business of Bausch Health Companies Inc.) INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 F-2 Condensed Consolidated Statements of Operations for the thre

Feb 22, 2019

Bausch + Lomb Announces FDA Approval Of LOTEMAX® SM (loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery

Bausch + Lomb announced FDA approval of LOTEMAX® SM, a new ophthalmic gel for treating postoperative inflammation and pain after ocular surgery. The formulation uses SubMicron Technology for better drug penetration and has shown significant efficacy in clinical trials.

Nov 2, 2017

Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (Latanoprostene Bunod Ophthalmic Solution), 0.024%

Bausch + Lomb and Nicox announced FDA approval for VYZULTA, a new treatment for glaucoma that lowers intraocular pressure. The drug, which has a dual mechanism of action, is expected to be available by year-end, providing a significant advancement in glaucoma management.

Apr 5, 2013

Bausch + Lomb Receives FDA Approval for PROLENSA™ (bromfenac ophthalmic solution) 0.07%

Bausch + Lomb announced FDA approval for PROLENSA, a once-daily NSAID for postoperative inflammation and pain after cataract surgery. The drug demonstrated superior efficacy in clinical studies, with a significant percentage of patients achieving pain relief and inflammation clearance.

May 28, 2009